Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1991 Dec;19(6):691-712.
doi: 10.1007/BF01080874.

Semiparametric analysis of non-steady-state pharmacodynamic data

Affiliations

Semiparametric analysis of non-steady-state pharmacodynamic data

D Verotta et al. J Pharmacokinet Biopharm. 1991 Dec.

Abstract

We present an approach to the analysis of pharmacodynamic (PD) data arising from non-steady-state experiments, meant to be used when only PD data, not pharmacokinetic (PK) data, are available. The approach allows estimation of the steady-state relationship between drug input and effect. The analysis is based on a model describing the time dependence of drug effect (E) on (unobserved) drug concentration (Ce) in an hypothetical effect compartment. The model consists of (i) a known model for the input rate of drug I(t), (ii) a parametric model; L(t, alpha) (a function of time t, and vector of parameters alpha), relating I to an observed variable X, (iii) a nonparametric model relating X to E. Ce is proportional to X. X (t) is given by I(t) * L(t, alpha)/AL, where L(t, alpha) = e-alpha 1t * sigma k m = 1 alpha 2k e-alpha 2k + 1t, sigma k m = 1 alpha 2k = 1, AL = integral of 0 infinity L(t) dt, and * indicates convolution. The nonparametric model relating X to E is a cubic spline, a function of X and a vector of (linear) parameters beta. The values of alpha and beta are chosen to minimize the sum of squared residuals between predicted and observed E. We also describe a similar model, generalizing a previously described one, to analyze PK/PD data. Applications of the approach to different drug-effect relationships (verapamil-PR interval, hydroxazine-wheal and flare, flecainide and/or verapamil-PR, and left ventricular ejection fraction) are reported.

PubMed Disclaimer

Similar articles

Cited by

References

    1. Farmaco Sci. 1968 Oct;23(10):907-18 - PubMed
    1. Am J Physiol. 1989 Apr;256(4 Pt 2):R1005-10 - PubMed
    1. Clin Pharmacol Ther. 1989 Jul;46(1):26-32 - PubMed
    1. Clin Pharmacol Ther. 1986 Jul;40(1):86-93 - PubMed
    1. J Allergy Clin Immunol. 1984 Jan;73(1 Pt 1):69-75 - PubMed

Publication types

LinkOut - more resources